Synapse - Azeez Farooki

Results (14)

Costs to Medicare of nonrecommended bone-modifying agent use for castration-sensitive prostate cancer

Journal Article

Mitchell, A. P.; Nemirovsky, D.; Mishra Meza, A.; Chakraborty, N.; Persaud, S.; Farooki, A.; Morris, M. J.
JCO Oncology Practice (2024)

Fulltext@MSK | Save

Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer

Journal Article

Mitchell, A. P.; Persaud, S.; Palyca, P.; Salner, A.; Farooki, A.; Ostroff, J. S.; Morris, M. J.; Chimonas, S.
Prostate (2024)

Fulltext@MSK | Save

Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer

Journal Article

Mitchell, A. P.; Mishra Meza, A.; Panageas, K. S.; Lipitz-Snyderman, A.; Farooki, A.; Morris, M. J.
Prostate Cancer and Prostatic Diseases (2023)

Fulltext@MSK | Save

Barriers to guideline-concordant use of bone modifying agents for prostate cancer

Meeting Abstract

Mitchell, A. P.; Persaud, S.; Chimonas, S.; Salner, A. L.; Palyca, P.; Farooki, A.; Ostroff, J. S.; Morris, M. J.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Bone remineralization of lytic lesions in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, dexamethasone +/- daratumumab induction regimen

Meeting Abstract

Meseha, M.; Abusamra, M.; Farooki, A.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Shah, U.; Lu, S.; Mailankody, S.; more...
Clinical Lymphoma, Myeloma and Leukemia (2022)

Fulltext@MSK | Save

Use of bone modifying agents for metastatic castrate-resistant prostate cancer

Meeting Abstract

Mitchell, A. P.; Mishra Meza, A.; Farooki, A.; Panageas, K.; Bach, P. B.; Lipitz-Snyderman, A.; Morris, M. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma

Journal Article

McPherson, V.; Reardon, B.; Bhayankara, A.; Scott, S. N.; Boyd, M. E.; Whiting, K.; Garcia-Grossman, I. R.; Regazzi, A. M.; McCoy, A. S.; Kim, P. H.; more...
Cancer (2020)

Fulltext@MSK | Save

Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score

Journal Article

Mariotti, V.; Page, D. B.; Davydov, O.; Hans, D.; Hudis, C. A.; Patil, S.; Kunte, S.; Girotra, M.; Farooki, A.; Fornier, M. N.
Journal of Bone Oncology (2017)

Fulltext@MSK | Save

A combined screening approach of Fracture (Fx) Risk Algorithm (FRAX) and Trabecular Bone Score (TBS) to identify osteoporotic-range fracture risk (ORFR) in breast cancer (BC) patients treated with adjuvant aromatase inhibitor (AI)

Meeting Abstract

Page, D. B.; Mariotti, V.; Davydov, O.; Patil, S.; Hans, D.; Hudis, C. A.; Farooki, A.; Fornier, M. N.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Risk assessment for severe hypocalcemia requiring hospitalization with denosumab

Meeting Abstract

Autio, K. A.; Farooki, A.; Glezerman, I.; Chan, A.; Barr, H. C.; Seyboth, B. M.; Schneider, C. W.; Heller, G.; Scher, H. I.; Morris, M. J.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save